Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer

Inclusion Criteria: * Subject was previously enrolled in a denosumab phase 3 study and participated in the Open-label Extension portion of that study. * Subject or subject's legally acceptable representative has provided informed consent. Exclusion Criteria: * Subject is of child bearing potential and planning to become pregnant within 7 months after the end of treatment. * Subject is of child bearing potential and is not willing to use, in combination with her partner, two highly effective methods of contraception during treatment and for 7 months after the end of treatment. * Subject has known sensitivity to any of the products to be administered during dosing. * Subject will not be available for protocol required study visits or procedures, to the best of the subject and investigator's knowledge. * Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures.